Related Experiment Video
Updated: Dec 24, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
A Ganoderma-Derived Compound Exerts Inhibitory Effect Through Formyl Peptide Receptor 2
Huirong Wang1,2, Xingrong Peng3, Yunjun Ge1
1Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macau, Macau.
A compound from Ganoderma, C18, inhibits inflammation by targeting formyl peptide receptor 2 (FPR2). This discovery offers a potential new avenue for developing anti-inflammatory therapies.
Area of Science:
- Immunology
- Pharmacology
- Natural Products
Background:
- Formyl peptide receptors (FPRs) are crucial for host defense and inflammation.
- FPRs are G protein-coupled receptors (GPCRs) expressed on phagocytes, making them therapeutic targets.
- Ganoderma (Lingzhi) is a medicinal herb with known anti-inflammatory properties.
Purpose of the Study:
- To identify novel anti-inflammatory agents from Ganoderma.
- To investigate the mechanism of action of Ganoderma-derived compounds on FPR signaling.
Main Methods:
- Screening of Ganoderma extracts for anti-inflammatory activity.
- Characterization of compound 18 (C18) from Ganoderma cochlear.
- Assessing C18's binding to FPR2 and its effects on receptor conformation and signaling.
Main Results:
- Compound 18 (C18) from Ganoderma cochlear was identified as an anti-inflammatory agent.
- C18 binds to FPR2, inducing a unique conformational change.
- C18 inhibits FPR2 signaling, reducing superoxide production and cell chemotaxis.
Conclusions:
- A Ganoderma-derived component (C18) inhibits inflammation via FPR2.
- This represents the first identification of a Ganoderma component acting through FPR2.
- Further optimization of C18 is needed for therapeutic applications.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
09:51Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Related Concept Videos
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...